This article raises some valid concerns: where does the data come from, do the authors have a financial interest?
Summarizing the article:
How many patient records do they claim to have reviewed?
The authors purport to have reviewed over 68,000 patient records from 169 hospitals around the world. Of the 68,000 reviewed, they selected 1,408 propensity-matched patients. The authors claim this data was accessed via a registry (mentioned below), but we have some questions about that registry.
What are their key points?
Well, they raise the question, does the antimicrobial drug, ivermectin, influence the outcome in COVID-19 illness? They answer by declaring that based on this observational propensity-matched case-controlled study in 1,408 patients (704 that received ivermectin and 704 that did not) demonstrates an association of ivermectin use with lower in-hospital mortality—1.4% versus 8.5% (Ivermectin vs. No Ivermectin); HR 0.20 CL 95%, 0.11-0.37, P.
What is their conclusion and Setting?
Ivermectin is associated with a potential survival benefit in COVID-19, and this should be investigated urgently in randomized controlled trials. The data is derived from an international multi-institutional de-identified healthcare outcomes database.
What was the study design?
An international, multicenter, observational propensity-score matched case-controlled study using prospectively collected data on patients diagnosed with COVID-19 between January 1, 2020 and March 31, 2020.
[-] TrumpLyftAlles | 1 points | May 14 2020 19:18:15
This article raises some valid concerns: where does the data come from, do the authors have a financial interest?
Summarizing the article:
How many patient records do they claim to have reviewed?
The authors purport to have reviewed over 68,000 patient records from 169 hospitals around the world. Of the 68,000 reviewed, they selected 1,408 propensity-matched patients. The authors claim this data was accessed via a registry (mentioned below), but we have some questions about that registry.
What are their key points?
Well, they raise the question, does the antimicrobial drug, ivermectin, influence the outcome in COVID-19 illness? They answer by declaring that based on this observational propensity-matched case-controlled study in 1,408 patients (704 that received ivermectin and 704 that did not) demonstrates an association of ivermectin use with lower in-hospital mortality—1.4% versus 8.5% (Ivermectin vs. No Ivermectin); HR 0.20 CL 95%, 0.11-0.37, P.
What is their conclusion and Setting?
Ivermectin is associated with a potential survival benefit in COVID-19, and this should be investigated urgently in randomized controlled trials. The data is derived from an international multi-institutional de-identified healthcare outcomes database.
What was the study design?
An international, multicenter, observational propensity-score matched case-controlled study using prospectively collected data on patients diagnosed with COVID-19 between January 1, 2020 and March 31, 2020.
permalink